CDK7 and cancer: Similarly, considering that CDK7 promotes YAP stabilization (and activity) by directly phosphorylating and preventing their degradation, preclinically available CDK7 inhibitors could be considered to blunt YAP/TAZ-dependent transcription in cancer cells [41].